- Fee assured
- Awaiting verification
- Paediatric oncology
Consultant paediatric oncologist, head of Children and Young People's Unit, Royal Marsden Hospital, practice includes adolescent and young adult patients with soft tissue sarcoma. Major interest in soft tissue sarcoma. Works with adult sarcoma team at Royal Marsden; board member of European Paediatric Soft Tissue Sarcoma Group and European lead for clinical trials in relapsed rhabdomyosarcoma
Areas of interest
paediatric solid tumours; paediatric and adolescent soft tissue sarcomas
Geoerger B, Chisholm JC et al, on behalf of the European Consortium for Innovative Therapies for Children with Cancer (ITCC) (2010). Phase II Study of Gemcitabine combined with Oxaliplatin in Relapsed or Refractory Pediatric Solid Malignancies: an Innovative Therapies for Children with Cancer European Consortium Study. European Journal of Cancer; 47(2):230-8. Epub 2010 Oct 11.
Chisholm JC, et al (2011). Prognostic factors after relapse in non-metastatic rhabdomyosarcoma – a nomogram to better define patients who can be salvaged with further therapy. Journal of Clinical Oncology. 29(10):1319-25. Epub 2011 Feb 28.
Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, et al(2011). DICER1 Syndrome – a Pleiotropic Tumor Predisposition Syndrome. J Med Genet. 2011 Jan 25.
Missiaglia E, Williamson D, Chisholm J, et al (2012). PAX3/FOXO1 Fusion gene status is the key predictive molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30 1670-7
George SL Broster S, Chisholm JC Brock P (2012). Docetaxel in the Treatment of Children With Refractory or Relapsed Hepatoblastoma . J Paediatr Haematol Oncol. Oct;34(7):e295-7.
Williamson D, Missiaglia E, Chisholm J, Shipley J. Inconvenience of convenience cohorts – letter. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1388.
Gibson F , Chisholm J , Blandford E Donachie P Hartley J , Lane S, Selwood K , Skinner R , Phillips R on behalf of the CCLG Supportive Care Group (2013). Developing a national ‘low risk’ febrile neutropenia framework for use in children and young people’s cancer care. Support Care Cancer. 2013 May;21(5):1241-51.
Schoot R, McHugh K, Rick R. van Rijn,. Kremer LCM, Chisholm JC, Caron H,. Merks JHM (2013). Response Assessment in Pediatric Rhabdomyosarcoma: Can the Response Evaluation Criteria for Solid Tumors (RECIST) Replace 3D Volume Assessments? Radiology 269(3):870-878.
Morgenstern D, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya, SJ Chisholm JC, Pearson A, Moreno L (2012). Early phase clinical trials in paediatric oncology: the Royal Marsden experience. J Pediatr Hematol Oncol 07 Dec 2013. epub ahead of print.
Reference number 3322620
Affiliations / memberships
UK Childrens Cancer and Leukaemia Group
European paediatric Soft Tissue Sarcoma Group (EpSSG)
Innovative Therapies for Childhood Cancer (ITCC)
- The Royal Marsden Hospital, SM2 5PT
- 09:00 - 13:00
- 020 8661 3549
Post treatment communication
Following treatment of a Bupa member, we will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Ask for paediatric registrar